Different regulatory pathways are involved in the proliferative inhibition of two types of leukemia cell lines induced by paclitaxel

Xia,Rui-Long; Lu,Yan; Zhu,Li-Na; Zhang,Shi-Fu; Zhao,Fu-Kun; Fu,Cai-Yun

doi:10.3892/or.2013.2624

Different regulatory pathways are involved in the proliferative inhibition of two types of leukemia cell lines induced by paclitaxel

Authors:
- Rui-Long Xia
- Yan Lu
- Li-Na Zhu
- Shi-Fu Zhang
- Fu-Kun Zhao
- Cai-Yun Fu
View Affiliations

Affiliations: Laboratory of Proteomics and Molecular Enzymology, School of Life Sciences, Zhejiang Sci-Tech Untiversity, Hangzhou, Zhejiang 10018, P.R. China
Published online on: July 18, 2013 https://doi.org/10.3892/or.2013.2624
Pages: 1853-1859

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Paclitaxel, one of the broadest-spectrum anticancer agents, is currently being used in the treatment of patients with solid tumors. In the present study, we compared the effect of paclitaxel on two types of leukemia cells. Our results showed that paclitaxel could inhibit the proliferation of MEL and K562 cells in a dose- and time-dependent manner. The mechanism of proliferative inhibition in K562 cells treated by paclitaxel was related to the cell cycle arrest in the G2/M phase, as well as the induction of apoptosis. By contrast, MEL cells treated by paclitaxel showed significant characteristics of necrosis, which indicated that the mode of cell death induced by paclitaxel in these two types of leukemia cells differed. Advances in research of the cell cycle, apoptosis and necrosis will extend our understanding of the mechanisms of paclitaxel-induced cell death, particularly in leukemia cells. Further elucidation of the mechanisms of necrosis in MEL cells may expedite the development of improved paclitaxel-based regimens for cancer therapy.

View Figures

View References

1	Burris HA III: Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin Oncol. 28:38–44. 2001. View Article : Google Scholar : PubMed/NCBI
2	Belani C and Lynch T: Docetaxel (Taxotere) in combination with platinums in patients with non-small cell lung cancer: trial data and implications for clinical management. Semin Oncol. 28:10–14. 2001. View Article : Google Scholar : PubMed/NCBI
3	Kaye S, Piccart M, Aapro M, Francis P and Kavanagh J: Phase II trials of docetaxel (taxotere^®) in advanced ovarian cancer - an updated overview. Eur J Cancer. 33:2167–2170. 1997. View Article : Google Scholar : PubMed/NCBI
4	Horwitz S: Taxol (paclitaxel): mechanisms of action. Ann Oncol. 5:S3–S6. 1994.
5	Monzó M, Rosell R, Sánchez JJ, Lee JS, O’Brate A, González-Larriba JL, Alberola V, Lorenzo JC, Núñez L, Ro JY and Martín C: Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol. 17:1786–1793. 1999.PubMed/NCBI
6	Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T and Poruchynsky MS: Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem. 272:17118–17125. 1997.
7	Ranganathan S, Benetatos C, Colarusso P, Dexter D and Hudes G: Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer. 77:562–566. 1998. View Article : Google Scholar : PubMed/NCBI
8	Wilson L, Bamburg J, Mizel S, Grisham L and Creswell K: Interaction of drugs with microtubule proteins. Fed Proc. 33:158–166. 1974.PubMed/NCBI
9	Bhalla K, Ibrado A, Tourkina E, Tang C, Mahoney M and Huang Y: Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia. 7:563–568. 1993.PubMed/NCBI
10	Havrilesky LJ, Elbendary A, Hurteau JA, Whitaker RS, Rodriguez GC and Berchuck AW: Chemotherapy-induced apoptosis in epithelial ovarian cancers. Obstet Gynecol. 85:1007–1010. 1995. View Article : Google Scholar : PubMed/NCBI
11	Chang YF, Li LL, Wu CW, Liu TY, Lui WY, P’eng FK and Chi CW: Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer. 77:14–18. 1998. View Article : Google Scholar : PubMed/NCBI
12	Yen WC, Wientjes MG and Au JLS: Differential effect of taxol in rat primary and metastatic prostate tumors: site-dependent pharmacodynamics. Pharm Res. 13:1305–1312. 1996. View Article : Google Scholar : PubMed/NCBI
13	Fallo F, Pilon C, Barzon L, Pistorello M, Pagotto U, Altavilla G, Boscaro M and Sonino N: Effects of taxol on the human NCI-H295 adrenocortical carcinoma cell line. Endocr Res. 22:709–715. 1996.PubMed/NCBI
14	Terzis AJ, Thorsen F, Heese O, Visted T, Bjerkvig R, Dahl O, Arnold H and Gundersen G: Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. Br J Cancer. 75:1744–1752. 1997. View Article : Google Scholar : PubMed/NCBI
15	Rowinsky EK: The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med. 48:353–374. 1997. View Article : Google Scholar : PubMed/NCBI
16	Al-Alami O, Sammons J, Martin J and Hassan H: Divergent effect of taxol on proliferation, apoptosis and nitric oxide production in MHH225 CD34 positive and U937 CD34 negative human leukaemia cells. Leuk Res. 22:939–945. 1998. View Article : Google Scholar : PubMed/NCBI
17	Richards W, Song MK, Krutzsch H, Evarts R, Marsden E and Thorgeirsson S: Measurement of cell proliferation in microculture using Hoechst 33342 for the rapid semiautomated microfluorimetric determination of chromatin DNA. Exp Cell Res. 159:235–246. 1985. View Article : Google Scholar
18	Shi Y, Wei Y, Qu S, Wang Y, Li Y and Li R: Arsenic induces apoptosis of human umbilical vein endothelial cells through mitochondrial pathways. Cardiovasc Toxicol. 10:153–160. 2010. View Article : Google Scholar : PubMed/NCBI
19	Gangemi RM, Tiso M, Marchetti C, Severi AB and Fabbi M: Taxol cytotoxicity on human leukemia cell lines is a function of their susceptibility to programmed cell death. Cancer Chemother Pharmacol. 36:385–392. 1995. View Article : Google Scholar : PubMed/NCBI
20	Haldar S, Basu A and Croce CM: Bcl2 is the guardian of microtubule integrity. Cancer Res. 57:229–233. 1997.PubMed/NCBI
21	Gangemi RM, Santamaria B, Bargellesi A, Cosulich E and Fabbi M: Late apoptotic effects of taxanes on K562 erythroleukemia cells: apoptosis is delayed upstream of caspase-3 activation. Int J Cancer. 85:527–533. 2000. View Article : Google Scholar : PubMed/NCBI
22	Seiter K, Feldman EJ, Traganos F, Li X, Halicka HD, Darzynkiewicz Z, Lederman CA, Romero MB and Ahmed T: Evaluation of in vivo induction of apoptosis in patients with acute leukemia treated on a phase I study of paclitaxel. Leukemia. 9:1961–1966. 1995.PubMed/NCBI
23	Consolini R, Pui C-H, Behm FG, Raimondi SC and Campana D: In vitro cytotoxicity of docetaxel in childhood acute leukemias. J Clin Oncol. 16:907–913. 1998.PubMed/NCBI
24	Ney PA and D’Andrea AD: Friend erythroleukemia revisited. Blood. 96:3675–3680. 2000.PubMed/NCBI
25	Friend C: Cell-free transmission in adult Swiss mice of a disease having the character of a leukemia. J Exp Med. 105:307–318. 1957. View Article : Google Scholar : PubMed/NCBI
26	Yusuf R, Duan Z, Lamendola D, Penson R and Seiden M: Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets. 3:1–19. 2003. View Article : Google Scholar : PubMed/NCBI
27	Wang TH, Wang HS and Soong YK: Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer. 88:2619–2628. 2000. View Article : Google Scholar : PubMed/NCBI
28	Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T and Traganos F: Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry. 27:1–20. 1997. View Article : Google Scholar : PubMed/NCBI
29	Majno G and Joris I: Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol. 146:3–15. 1995.PubMed/NCBI